146 related articles for article (PubMed ID: 9628546)
1. The selective estrogen receptor modulator, raloxifene: an overview of nonclinical pharmacology and reproductive and developmental testing.
Buelke-Sam J; Bryant HU; Francis PC
Reprod Toxicol; 1998; 12(3):217-21. PubMed ID: 9628546
[TBL] [Abstract][Full Text] [Related]
2. The selective estrogen receptor modulator, raloxifene: a segment II/III delivery study in rats.
Buelke-Sam J; Cohen IR; Wierda D; Griffey KI; Fisher LF; Francis PC
Reprod Toxicol; 1998; 12(3):271-88. PubMed ID: 9628551
[TBL] [Abstract][Full Text] [Related]
3. The selective estrogen receptor modulator, raloxifene: segment II studies in rats and rabbits.
Byrd RA; Francis PC
Reprod Toxicol; 1998; 12(3):261-70. PubMed ID: 9628550
[TBL] [Abstract][Full Text] [Related]
4. The selective estrogen receptor modulator, raloxifene: reproductive assessments following preimplantation exposure in mated female rats.
Clarke DO; Griffey KI; Buelke-Sam J; Francis PC
Reprod Toxicol; 1998; 12(3):247-59. PubMed ID: 9628549
[TBL] [Abstract][Full Text] [Related]
5. The selective estrogen receptor modulator, raloxifene: reproductive assessments following premating exposure in female rats.
Hoyt JA; Fisher LF; Buelke-Sam JL; Francis PC
Reprod Toxicol; 1998; 12(3):233-45. PubMed ID: 9628548
[TBL] [Abstract][Full Text] [Related]
6. Endocrine and antiprostatic effects of raloxifene (LY156758) in the male rat.
Neubauer BL; Best KL; Clemens JA; Gates CA; Goode RL; Jones CD; Laughlin ME; Shaar CJ; Toomey RE; Hoover DM
Prostate; 1993; 23(3):245-62. PubMed ID: 8234067
[TBL] [Abstract][Full Text] [Related]
7. The selective estrogen receptor modulator, raloxifene: reproductive assessments in adult male rats.
Hoyt JA; Fisher LF; Swisher DK; Byrd RA; Francis PC
Reprod Toxicol; 1998; 12(3):223-32. PubMed ID: 9628547
[TBL] [Abstract][Full Text] [Related]
8. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.
Black LJ; Sato M; Rowley ER; Magee DE; Bekele A; Williams DC; Cullinan GJ; Bendele R; Kauffman RF; Bensch WR
J Clin Invest; 1994 Jan; 93(1):63-9. PubMed ID: 8282823
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene.
Grese TA; Cho S; Finley DR; Godfrey AG; Jones CD; Lugar CW; Martin MJ; Matsumoto K; Pennington LD; Winter MA; Adrian MD; Cole HW; Magee DE; Phillips DL; Rowley ER; Short LL; Glasebrook AL; Bryant HU
J Med Chem; 1997 Jan; 40(2):146-67. PubMed ID: 9003514
[TBL] [Abstract][Full Text] [Related]
10. LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo.
Sato M; Turner CH; Wang T; Adrian MD; Rowley E; Bryant HU
J Pharmacol Exp Ther; 1998 Oct; 287(1):1-7. PubMed ID: 9765314
[TBL] [Abstract][Full Text] [Related]
11. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate.
Frolik CA; Bryant HU; Black EC; Magee DE; Chandrasekhar S
Bone; 1996 Jun; 18(6):621-7. PubMed ID: 8806005
[TBL] [Abstract][Full Text] [Related]
12. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats.
Sato M; Rippy MK; Bryant HU
FASEB J; 1996 Jun; 10(8):905-12. PubMed ID: 8666168
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators.
Grese TA; Pennington LD; Sluka JP; Adrian MD; Cole HW; Fuson TR; Magee DE; Phillips DL; Rowley ER; Shetler PK; Short LL; Venugopalan M; Yang NN; Sato M; Glasebrook AL; Bryant HU
J Med Chem; 1998 Apr; 41(8):1272-83. PubMed ID: 9548817
[TBL] [Abstract][Full Text] [Related]
14. An estrogen receptor basis for raloxifene action in bone.
Bryant HU; Glasebrook AL; Yang NN; Sato M
J Steroid Biochem Mol Biol; 1999; 69(1-6):37-44. PubMed ID: 10418979
[TBL] [Abstract][Full Text] [Related]
15. Effects of SP500263, a novel selective estrogen receptor modulator, on bone, uterus, and serum cholesterol in the ovariectomized rat.
Sutherland MK; Brady H; Gayo-Fung LM; Leisten J; Lipps SG; McKie JA; O'Leary E; Patnaik N; Anderson DW; Bhagwat SS; Stein B
Calcif Tissue Int; 2003 Jun; 72(6):710-6. PubMed ID: 14563000
[TBL] [Abstract][Full Text] [Related]
16. Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia.
Evans GL; Bryant HU; Magee DE; Turner RT
Endocrinology; 1996 Oct; 137(10):4139-44. PubMed ID: 8828469
[TBL] [Abstract][Full Text] [Related]
17. Hypocholesterolemic activity of raloxifene (LY139481): pharmacological characterization as a selective estrogen receptor modulator.
Kauffman RF; Bensch WR; Roudebush RE; Cole HW; Bean JS; Phillips DL; Monroe A; Cullinan GJ; Glasebrook AL; Bryant HU
J Pharmacol Exp Ther; 1997 Jan; 280(1):146-53. PubMed ID: 8996192
[TBL] [Abstract][Full Text] [Related]
18. The effects of raloxifene on tibia histomorphometry in ovariectomized rats.
Evans G; Bryant HU; Magee D; Sato M; Turner RT
Endocrinology; 1994 May; 134(5):2283-8. PubMed ID: 8156931
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological actions of a novel, potent, tissue-selective benzopyran estrogen.
Galbiati E; Caruso PL; Amari G; Armani E; Ghirardi S; Delcanale M; Civelli M
J Pharmacol Exp Ther; 2002 Oct; 303(1):196-203. PubMed ID: 12235251
[TBL] [Abstract][Full Text] [Related]
20. Selective estrogen receptor modulators: an alternative to hormone replacement therapy.
Bryant HU; Dere WH
Proc Soc Exp Biol Med; 1998 Jan; 217(1):45-52. PubMed ID: 9421206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]